IFNG and colitis: C. jejuni–mediated intestinal pathology during the early stage of infection is driven by innate immune response.47,52 IFNγ-producing ILCs contribute to C. jejuni-driven colitis.14 Our results demonstrate that tofacitinib treatment ameliorates intestinal pathology, similarly to studies using IFNγ depletion.13,14 Since tofacitinib ameliorated intestinal pathology and reduced IFNγ expression in the colon, we focused on IFNγ-producing cells.